Pivotal Therapeutics Announces First Quarter 2013 Financial Results
WOODBRIDGE, ON, May 29, 2013 /PRNewswire/ – Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, announced its
financial results and operational highlights for the three months ended
March 31, 2013. All dollar amounts referenced herein are in Canadian
dollars unless otherwise stated.
For the three months ended March 31, 2013 the Company reported a loss of
$783,436, or $0.01 per common share, compared with a loss of $831,090
or $0.01 per common share for the three months ended March 31, 2012.
At March 31, 2013, Pivotal’s working capital totaled $493,895 compared
with $452,914 at December 31, 2012.
“Our pilot marketing program for VASCAZEN continues to gain traction,
with initial sales up more than 200% from the previous quarter.
Furthermore, the pilot program continues to provide valuable
information which we are incorporating into our plans for our full
launch of VASCAZEN in 2013,” said Mr. Eugene Bortoluzzi Chief Executive
Officer and Chief Financial Officer. “After presenting our positive
results from our recently concluded VASCAZEN((R))-REVEAL clinical trial, healthcare professionals are realizing the benefits of Vascazen((R) )and how treating an Omega-3 deficiency can address risk factors for
The audited consolidated financial statements, accompanying notes to the
audited thereto and Management’s Discussion and Analysis for the three
months ended March 31, 2013, will be accessible on SEDAR www.sedar.com, CNSX www.cnsx.ca under the symbol “PVO” and OTCQX www.otcqx.com under the symbol “PVTTF”.
Pivotal highlights since December 31, 2012
-- March 6, 2013 - Pivotal exhibited at the American College of Cardiology's 62nd Annual Scientific Session and Expo; -- April 9, 2013 - Vascazen(R)-Top line results accepted for presentation at the American Heart Association's ATVB 2013 Scientific Sessions; -- April 30, 2013 - Pivotal announced presentation entitled "Treatment of Omega-3 Nutritional Deficiency Improves Cardiovascular Disease Risk Factors: Results of the Randomized, Double-Blind, Placebo-Controlled VASCAZEN(R)- REVEAL Trial" at the American Heart Association's ATVB 2013 Scientific Sessions; -- May 2, 2013 - Pivotal's founder, Chairman and Chief Scientific Officers Dr. Jackowski honoured with Queen Elizabeth's Diamond Jubilee Medal for his contribution to Canadian biotech and the significant improvement in the quality of life and care for cardiac patients with the development of the rapid format cardiac blood test; -- May 7, 2013 - VASCAZEN(R)- REVEALtrial meets primary and secondary endpoints, in eight weeks of treatment with VASCAZEN(R)patients corrected an Omega-3 deficiency with positive concomitant effects on their lipid profiles, mainly a 48% reduction of triglycerides and a raise of HDL without negative impact on the LDL-C lipid profile.
Pivotal s Goals for 2013:
-- Advance commercialization of Vascazen(R)with full launchin the U.S.; -- Expansion of the sales & marketing team; -- Initiation of new clinical trials; -- Completion of existing clinical trials for Vascazen(R)and publication of scientific data; -- Expansion of intellectual property portfolio; -- Investigation of international licensing opportunities; -- Expansion of product offerings; -- Investment community presentations to increase awareness; -- Presentations and attendance at scientific meetings.
Notice of Annual General Meeting
Pivotal Therapeutics Inc. will hold its Annual General Meeting of
Shareholders at 10:00 AM on June 26, 2013 at the registered office of
the Company, 81 Zenway Blvd., Unit 10, Woodbridge, Ontario.
VASCAZEN((R)) is currently available in the U.S. as a prescription only Medical Food
specifically formulated for the dietary management of an Omega-3
deficiency in cardiovascular patients. VASCAZEN((R)) is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents. VASCAZEN((R) )is the second to market prescription only Omega-3 in the U.S. and is
available by prescription nationwide.
VASCAZEN((R)) has been clinically shown to correct an Omega-3 deficiency within 8
weeks of treatment with positive concomitant effects on the lipid
profiles, mainly a 48% reduction of triglycerides and a raise of HDL
without negative impact on the LDL-C lipid profile. VASCAZEN((R))‘s results were achieved with a dose of 3 grams of EPA and DHA per day
of a prescription grade, high purity Omega-3.
About Pivotal Therapeutics Inc.
Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics’ lead product VASCAZEN((R)) is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications. OMAZEN(TM) is a prescription grade Omega-3 providing >90% total Omega-3 in each
capsule with a unique 6:1 ratio of EPA:DHA. OMAZEN(TM) is a patented product available for sale and distribution in Canada.
The information contained in this document is as of May 29, 2013. This
press release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal’s actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as “will”,
“anticipate”, “estimate”, “expect”, “project”, “forecast”, “intend”,
“plan”, “believe”, “project”, “potential”, and similar expressions with
any discussion of future operating or financial performance or events.
In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal’s inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to compete
with others who provide comparable products; risk that the Company’s
products will not gain widespread market acceptance; risks relating to
the Company’s ability to maintain its CSNX listing. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. The Company undertakes no obligation to publicly
update or revise any forward-looking statements contained in this
document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.